Skip to main content

psychedelic assisted therapy

Special Issue on Contextual Behavioral Science and the Psychedelic Renaissance; Guest Edited by Jason Luoma, Lance McCracken, Rosalind Watts and Alan Kooi Davis

Scientific research into psychedelic agents is undergoing a renaissance. Decades after clinical research into the therapeutic value of psychedelic compounds was halted, significant clinical research restarted in the 1990s and has been rapidly accelerating in recent years. To date, clinical research has demonstrated preliminary efficacy and safety of psychedelic compounds across a number of clinical presentations, with research currently heading into Phase III trials that will conceivably lead to regulatory changes allowing the prescription of at least some psychedelic compounds.

Subscribe to psychedelic assisted therapy